SKP2 and prostate neoplasm: Targeting post‐translational regulatory mechanisms for FOXA1 through SKP2 inhibition (SZL P1‐41) reduced prostate tumor proliferation, and restored luminal phenotypes and FOXA1 levels, supporting enhanced therapeutic sensitivity in advanced stages of PCa.